Skip to Content


Active Substance: arcitumomab
Common Name: arcitumomab
ATC Code: V09IA01
Marketing Authorisation Holder: Immunomedics GmbH
Active Substance: arcitumomab
Status: Withdrawn
Authorisation Date: 1996-10-04
Therapeutic Area: Radionuclide Imaging Colorectal Neoplasms
Pharmacotherapeutic Group: Diagnostic radiopharmaceuticals

Therapeutic Indication

CEA-Scan is indicated only in patients with histologically-demonstrated carcinoma of the colon or rectum for imaging of recurrence and/or metastases. CEA-Scan is employed for diagnostic use only, in the above mentioned patients, as an adjunct to standard non-invasive imaging techniques, such as ultrasonography or CT scan, in the following situations:

  • Patients with evidence of recurrence and/or metastatic carcinoma of the colon or rectum, who are undergoing an evaluation for extent of disease, such as prior to surgical resection and/or other therapy, or
  • Patients with suspected recurrence and/or metastatic carcinoma of the colon or rectum in association with rising levels of carcinoembryonic antigen (CEA).

The marketing authorisation for CEA-Scan has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.